IMMUNE-MEDIATED DISEASES
Publications (246) Publications in which a researcher has participated
2025
-
Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry
Arthritis research & therapy, Vol. 27, Núm. 1, pp. 5
-
Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry
Arthritis Research and Therapy, Vol. 27, Núm. 1
2024
-
18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry
Journal of Clinical Medicine, Vol. 13, Núm. 20
-
Artritis idiopática juvenil oligoarticular
Manual SER de diagnóstico y tratamiento en reumatología pediátrica (Ergon), pp. 49-55
-
Artropatía en la enfermedad inflamatoria intestinal
Manual SER de diagnóstico y tratamiento en reumatología pediátrica (Ergon), pp. 117-122
-
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
Seminars in Arthritis and Rheumatism, Vol. 64
-
Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion
Rheumatology International, Vol. 44, Núm. 11, pp. 2327-2336
-
Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis
European Journal of Internal Medicine, Vol. 129, pp. 78-86
-
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature
Arthritis Research and Therapy, Vol. 26, Núm. 1
-
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register
RMD open, Vol. 10, Núm. 1
-
Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options
International Journal of Molecular Sciences, Vol. 25, Núm. 13
-
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199
-
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338
-
PERSISTENCE, EFFECTIVENESS, AND SAFETY OF UPADACITINIB IN CROHN'S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: RESULTS FROM A SPANISH NATIONWIDE STUDY (UREAL STUDY)
American Journal of Gastroenterology
-
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Science and Medicine, Vol. 11, Núm. 1
-
Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes
Genome Biology, Vol. 25, Núm. 1
-
Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients
RMD open, Vol. 10, Núm. 2
-
Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients
Seminars in Arthritis and Rheumatism, Vol. 68
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
-
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU
Gut